MGNX Overview
Upcoming Projects (MGNX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MGNX)
-
Discussing MacroGenics' Recent TAMARACK Phase 2 data for Vobra Duo in mCRPC Patients at ESMO Congress 2024.
Ticker: MGNX
Executed On: Oct 24, 2024 at 03:00 PM EDT
Upcoming & Overdue Catalysts (MGNX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MGNX)
-
MacroGenics (MGNX) to complete Phase 3 study of Margetuximab in treatment of HER2+ Metastatic Breast Cancer in 2018
Ticker: MGNX
Occurred on: Jan 23, 2018 -
Macrogenics' Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at ASCO
Ticker: MGNX
Occurred on: Jan 18, 2018 -
MacroGenics (MGNX) Fourth Quarter and Full Year 2015 Financial Results Conference Call to be held February 29th
Ticker: MGNX
Occurred on: Feb 29, 2016 -
MacroGenics (MGNX) Presents Data from Ongoing Phase 1 Study of Enoblituzumab in Several Tumor Types at 30th Annual SITC Meeting
Ticker: MGNX
Occurred on: Nov 07, 2015 -
Publication in PLOS Pathogens Demonstrates Potential of MacroGenics' (MGNX) DART Molecules in Eliminating HIV
Ticker: MGNX
Occurred on: Nov 05, 2015
Strategic Initiatives (MGNX)
-
Macrogen and Silicon Biosystems Menarini to Co-Develop CLIA-Certified Genomic Cancer Assays
Tickers: MGNX, Silicon Biosystems
Announcement Date: Feb 12, 2016
